Stattic is primarily used in biomedical research as a selective inhibitor of STAT3 (Signal Transducer and Activator of Transcription 3), a protein involved in cell signaling pathways linked to cancer and inflammation. It effectively blocks STAT3 activation and dimerization, making it a valuable tool for studying tumor growth, survival, and resistance to therapy. Researchers use Stattic to investigate its effects in various cancer models, including breast, lung, prostate, and blood cancers, where STAT3 is often overactive. It has also been explored for its potential to enhance the effectiveness of other anticancer therapies by overcoming drug resistance. Due to its ability to induce apoptosis and inhibit proliferation in cancer cells, Stattic supports the development of targeted therapies. However, it is mainly restricted to laboratory use and not approved for clinical treatment.